Pazopanib, with or without pembrolizumab, for metastatic soft-tissue cancer
Part of Cancer clinical trials.
This Phase 2 trial tests pazopanib alone or together with pembrolizumab to slow or shrink metastatic soft-tissue sarcoma after prior chemotherapy. It may help some people by strengthening the anti-cancer effect compared with pazopanib by itself.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 to 80 years old at the time you start the study.
- Your soft-tissue sarcoma has spread (metastasized) and has progressed after 1 or 2 prior chemotherapy treatments (but you must not have certain pazopanib-resistant cancer types).
- You are well enough to do daily activities: ECOG 0 or 1.
- Your scans show at least one measurable tumor spot that can be tracked over time.
- Your blood and organ tests are adequate (for example: hemoglobin at least 9, neutrophils and platelets high enough, and liver/kidney tests within allowed limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This Phase 2 trial tests whether pemetrexed plus cisplatin can shrink advanced or metastatic soft tissue sarcoma. It may help people whose cancer has spread and who can safely receive chemotherapy.
This trial tests a combination of two drugs, palbociclib and pembrolizumab, in people with certain types of advanced sarcoma (cancer of the soft tissues) that have continued to grow despite prior treatment. It aims to see if this combination can shrink tumors or slow down the cancer.
This Phase 2 trial studies whether combining pembrolizumab and cabozantinib can control advanced sarcoma that can’t be removed by surgery and has grown or returned after standard treatment. It may help shrink tumors and improve outcomes in adults who have limited treatment options left.
Hear when a new Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.